The psychopharmacology of GABA synapses: update 1989

  • K. G. Lloyd
  • P. Pichat
  • B. Scatton
  • B. Zivkovic
  • P. L. Morselli
  • G. Bartholini
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 29)


Recent advances in the psychopharmacology of GABA synapses are reviewed. The usefulness of GABA mimetics in tardive dyskinesia and epilepsy has been confirmed, as has a dysfunction of GABA synapses in the etiopathology of these conditions. The antidepressant profile of GABA agonists in animal models for depression has been extended. The role of GABA receptors in the mechanism of action of antidepressants has been further delineated, with a parallelism occurring between the behavioral and biochemical response to antidepressant drug treatment in different animal models of depression.


Tardive Dyskinesia Gaba Neuron Gaba Agonist Bioi Psychiatry Vacuous Chewing Movement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aley KO, Kulkarni SK (1988) Studies on the neuropsychopharmacological profile of fen-gabine (SL 79229) in mice. Meth Find Exptl Clin Pharmacol 10: 563–568.Google Scholar
  2. Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C (1987) Baclofen in the treatment of tardive dyskinesia. Curr Ther Res 42: 111–114.Google Scholar
  3. Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK (1986) Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer’s disease. Arch Gen Psychiatry 43: 1143–1147.PubMedCrossRefGoogle Scholar
  4. Bartholini G, Scatton B, Zivkovic B, Lloyd KG (1986) GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 79–83.Google Scholar
  5. Bennett JP Jr (1986) Striatal dopamine depletion, dopamine receptor stimulation, and GABA metabolism: implications for the therapy of Parkinson’s disease. Ann Neurol 19: 194–197.PubMedCrossRefGoogle Scholar
  6. Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36: 927–934.PubMedCrossRefGoogle Scholar
  7. Bennett JP Jr, Ferrari MB, Cruz CJ (1987) GABA-mimetic drugs enhance apomorphine-induced contralateral turning in rats with unilateral nigrostriatal dopamine denervation: implications for the therapy of Parkinson’s disease. Ann Neurol 21: 41–45.PubMedCrossRefGoogle Scholar
  8. Bergman SA, Wynn RL, Peterson MD, Rudo FG (1988) GABA agonists enhance morphine and fentanyl antinociception in rabbit tooth pulp and mouse hot plate assays. Drug Dev Res 14: 111–122.CrossRefGoogle Scholar
  9. Borsini F, Mancinelli A, D’Aranno V, Evangelista S, Meli A (1988) On the role of endogenous GABA in the forced swimming test in rats. Pharmacol Biochem Behav 29: 275–279.PubMedCrossRefGoogle Scholar
  10. Brailowsky S, Kunimoto M, Menini Ch, Silva-Barrat C, Riche D, Naquet R (1988) The GABA withdrawal syndrome: a new model of focal epileptogenesis. Brain Res 442: 175–179.PubMedCrossRefGoogle Scholar
  11. Brioni JD, McGaugh JL (1988) Post-training administration of GABAergic antagonists enhances retention of aversively motivated tasks. Psychopharmacology 96: 505–510.PubMedCrossRefGoogle Scholar
  12. Caboche J, Mitrovic N, Le Saux F, Besson M-J, Sauter A, Maurin Y (1989) Postnatal evolution of the γ-aminobutyric acid/benzodiazepine receptor complex in a model of inherited epilepsy: the quaking mouse. J Neurochem 52: 419–427.PubMedCrossRefGoogle Scholar
  13. Castellano C, Pavone F (1988) Effects of ethanol on passive avoidance behaviour in the mouse: involvement of GABAergic mechanisms. Pharmacol Biochem Behav 29: 321–324.PubMedCrossRefGoogle Scholar
  14. Cheetham SC, Crompton MR, Katona CLE, Parker SJ, Horton RW (1988) Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 460: 114–123.PubMedCrossRefGoogle Scholar
  15. Cheng S-C, Brunner EA (1985) Inducing anesthesia with a GABA analog, THIP. Anes-thesiology 63: 147–151.Google Scholar
  16. Chopra K, Kunchandy J, Kulkarni SK (1988) Benzodiazepine inverse agonsit FG-7142-induced delayed behavioral depression in mice. Arch Int Pharmacodyn 294: 56–63.PubMedGoogle Scholar
  17. Chu DCM, Penney JB Jr, Young AB (1987a) Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer’s disease. Neurosci Lett 82: 246–252.PubMedCrossRefGoogle Scholar
  18. Chu DCM, Penney JB Jr, Young AB (1987b) Cortical GABAB and GABAA receptors in Alzheimer’s disease: a quantitative autoradiographic study. Neurology 37: 1454–1459.PubMedGoogle Scholar
  19. Corradetti R, Ruggiero M, Chiarugi VP, Pepeu G (1987) GABA-receptor stimulation enhances norepinephrine-induced polyphosphoinositide metabolism in rat hippocampal slices. Brain Res 411: 196–199.PubMedCrossRefGoogle Scholar
  20. Cross JA, Cheetham SC, Crompton MR, Katona CLE, Horton RW (1988) Brain GABAB binding sites in depressed suicide victims. Psychiatry Res 26: 119–129.PubMedCrossRefGoogle Scholar
  21. Cross JA, Horton RW (1988) Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABAB binding sites: a comparison with 5-HT2 binding site changes. Br J Pharmacol 93: 331–336.PubMedGoogle Scholar
  22. Czudek C, Reynolds GP (1987) [3H] Muscimol binding to post-mortem brain tissue in schizophrenia. Br J Pharmacol 91: 342P.Google Scholar
  23. Czudek C, Reynolds GP (1988) [3H] Nipecotic acid binding to GABA uptake sites in the amygdala in schizophrenia. Br J Pharmacol 95: 899P.Google Scholar
  24. Decsi L, Nagy J (1988) Independent GABAergic and cholinergic modulation of apomor-phine-induced stereotyped rearing in the rat. Neuropharmacology 27: 281–285.PubMedCrossRefGoogle Scholar
  25. Depaulis A, Morgan MM, Liebeskind JC (1987) GABAergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal gray matter of the rat. Brain Res 436: 223–238.PubMedCrossRefGoogle Scholar
  26. Depaulis A, Vergnes M, Marescaux C, Lannes B, Warter J-M (1988) Evidence that activation of GABA receptors in the substantia nigra suppresses spontaneous spike-and-wave discharges in the rat. Brain Res 448: 20–29.PubMedCrossRefGoogle Scholar
  27. Drower EJ, Hammond DL (1988) GABAergic modulation of nociceptive threshold: effects of THIP and bicuculline microinjected in the ventral medulla of the rat. Brain Res 450: 316–324.PubMedCrossRefGoogle Scholar
  28. Duka T, Goerke D, Dorow R, Höller L, Fichte K (1988) Human studies on the benzo-diazepine receptor antagonist β-carboline ZK 93426: antagonism of lormetazepam’s psychotropic effects. Psychopharmacology 95: 463–471.PubMedCrossRefGoogle Scholar
  29. Evangelista S, Borsini F, Meli A (1987) Evidence that muscimol acts in the forced swimming test by activating the rat dopaminergic system. Life Sci 41: 2679–2684.PubMedCrossRefGoogle Scholar
  30. Ferrarese C, Stasi MA, Samanin R, Vezzani A (1988) Seizure activity of two peptides derived from diazepam binding inhibitor (DBI) after intrahippocampal injection in rats. Soc Neurosci Abstr 14: 6.Google Scholar
  31. Fromm GH, Terrence CF (1987) Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology 37: 1725–1728.PubMedGoogle Scholar
  32. Guilarte TR, Block LD, Wagner HN Jr (1988) The putative endogenous convulsant 3-hydroxykynurenine decreases benzodiazepine receptor binding affinity: implications to seizures associated with neonatal vitamin B-6 deficiency. Pharmacol Biochem Behav 30: 665–668.PubMedCrossRefGoogle Scholar
  33. Gunne LM, Bachus SE, Gale K (1988) Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesia. Exp Neurol 100: 459–469.PubMedCrossRefGoogle Scholar
  34. Hanada S, Mita T, Nishino N, Tanaka C (1987) [3H] Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40: 259–266.PubMedCrossRefGoogle Scholar
  35. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P, O’Carroll A-M, Lofdahl E, Winblad B (1987) A disorder of cortical GABAergic innervation in Alzheimer’s disease. Neurosci Lett 73: 192–196.PubMedCrossRefGoogle Scholar
  36. Heit MC, Schwark WS (1988) Pharmacological studies with a GABA uptake inhibitor in rats with kindled seizures in the amygdala. Neuropharmacology 27: 367–374.PubMedCrossRefGoogle Scholar
  37. Iversen LL (1978) Biochemical psychopharmacology of GABA. In: Lipton Ma, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 25–38.Google Scholar
  38. Joly D, Lloyd KG, Pichat Ph, Sanger DJ (1987) Correlation between the behavioral effect of desipramine and GABAB receptor regulation in the olfactory bulbectomized rat. Br J Pharmacol 90: 125P.Google Scholar
  39. Jones RSG (1988) Epileptiform events induced by GABA antagonists in entorhinal cortical cells in vitro are partly mediated by N-methyl-D-aspartate receptors. Brain Res 457: 113–121.PubMedCrossRefGoogle Scholar
  40. Karbon EW, Duman R, Enna SJ (1987) GABAB receptors and norepinephrine-stimulated cAmP production in rat brain cortex. Brain Res 306: 327–332.CrossRefGoogle Scholar
  41. Kimber JR, Cross JA, Horton RW (1987) Benzodiazepine and GABAA receptors in rat brain following chronic antidepressant drug administration. Biochem Pharmacol 36: 4173–4175.PubMedCrossRefGoogle Scholar
  42. Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang L-J, Shannak K, Hornykiewicz O (1986) Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson’s disease: correlation with striatal dopamine loss. Ann Neurol 20: 26–31.PubMedCrossRefGoogle Scholar
  43. Kumar BA, Forster MJ, Lal H (1988) CGS 8216, a benzodiazepine receptor antagonist, enhances learning and memory in mice. Brain Res 460: 195–198.PubMedCrossRefGoogle Scholar
  44. Le Gal La Salle G, Brailowsky S, Menini Ch, Naquet R (1988) Local asymptomatic status epilepticus induced by withdrawal of GABA infusion into limbic structures. Exp Neurol 101: 411–417.CrossRefGoogle Scholar
  45. Lister RG (1985) The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 9: 87–94.PubMedCrossRefGoogle Scholar
  46. Lloyd KG (1989) GABA and depression. In: Nistico G, Bowery NG (eds) GABA from basic research to clinical applications. Pythagora Press, Rome, pp 301–343.Google Scholar
  47. Lloyd KG, Morselli PL (1987) Psychopharmacology of GABAergic drugs. In: Meltzer HY (ed) Psychopharmacology: a third generation of progress. Raven Press, New York, pp 183–195.Google Scholar
  48. Lloyd KG, Pichat Ph (1986) Decrease in GABAB binding to the frontal cortex of olfactory bulbectomized rats. Br J Pharmacol 87: 36P.Google Scholar
  49. Lloyd KG, Thuret F, Pilc A (1985) Upregulation of γ-aminobutyric acid (GABA)B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 235: 191–199.PubMedGoogle Scholar
  50. Lloyd KG, Zivkovic B, Sanger DJ, Depoortere H, Bartholini G (1987) Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 241: 245–250.PubMedGoogle Scholar
  51. Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G (1989) The GABAergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 13: 341–351.PubMedCrossRefGoogle Scholar
  52. Lovick TA (1987) Tonic GABAergic and cholinergic influences on pain control and cardiovascular control neurones in nucleus paragigantocellularis lateralis in the rat. Pain 31: 401–409.PubMedCrossRefGoogle Scholar
  53. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM (1988) Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain 111: 785–799.PubMedCrossRefGoogle Scholar
  54. Mithani S, Atmadja S, Baimbridge KG, Fibiger HC (1987) Neuroleptic-induced oral dys-kinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology 93: 94–100.PubMedCrossRefGoogle Scholar
  55. Morselli PL (1988) GABAmimetics drugs and movement disorders. In: Nappi G et al. (eds) Neurodegenerative disorders: the role played by endotoxins and xenobiotics. Raven Press, New York, pp 171–178.Google Scholar
  56. Morselli PL, Priore P, Loeb C, Albano C, Nielsen NP, Serrati C, Musch B (1989) Anti-depressant activity of progabide and fengabine. In: Lerer B, et al (eds) New directions in affective disorders. Springer, Berlin Heidelberg New York Tokyo, pp 660–664.CrossRefGoogle Scholar
  57. Nabeshima T, Noda Y, Kameyama T (1988) GABAergic modulation of memory with regard to passive avoidance and conditioned suppression tasks in mice. Psychopharmacology 94: 69–73.PubMedCrossRefGoogle Scholar
  58. Nasrallah HA, Dunner FJ, McCalley-Whitters M (1985) A placebo-controlled trial of valproate in tardive dyskinesia. Biol Psychiatry 20: 199–228.Google Scholar
  59. Nguyen J, Thaker G, Tamminga C (1988) Progabide treatment of tardive dyskinesia. In preparation.Google Scholar
  60. Novas ML, Wolfman C, Medina JH, De Robertis E (1988) Proconvulsant and “anxiogenic” effects of n-buty β carboline-3-carboxylate, an endogenous benzodiazepine binding inhibitor from brain. Pharmacol Biochem Behav 30: 331–336.PubMedCrossRefGoogle Scholar
  61. Onténiente B, Simon H, Taghzouti K, Geffard M, Le Moal M, Calas A (1987) Dopamine-GABA interactions in the nucleus accumbens and lateral septum of the rat. Brain Res 421: 391–396.PubMedCrossRefGoogle Scholar
  62. Ossowska K, Wedzony K, Wolfarth S (1984) The role of the GABA mechanisms of the globus pallidus in mediating catalepsy, stereotypy and locomotor activity. Pharmacol Biochem Behav 21: 825–831.PubMedCrossRefGoogle Scholar
  63. Perrault G, Morel E, Joly D, Sanger DJ, Zivkovic B (1989) Antidepressant profile of SL 81.0385, a novel selective serotonin uptake inhibitor. In: Proceedings of the International Symposium on Serotonin, from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
  64. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter abnormalities in senile dementia. J Neurol Sci 34: 247–265.PubMedCrossRefGoogle Scholar
  65. Pilc A, Lloyd KG (1984) Chronic antidepressant and GABA “B” receptors: a GABA hypothesis of antidepressant drug action. Life Sci 35: 2149–2154.PubMedCrossRefGoogle Scholar
  66. Poncelet M, Martin P, Danti S, Simon P, Soubrie P (1987) Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals. Pharmacol Biochem Behav 28: 321–326.PubMedCrossRefGoogle Scholar
  67. Riekkinen PJ, Pitkänen A, Halonen T, Lehtinen M, Ylinen A, Sivenius J (1988) Effect of gamma-vinyl GABA treatment on cholinergic and aminergic neurotransmission and on cyclic nucleotides in human complex partial epilepsy—a CSF study. Prog Neuro-psychopharmacol Biol Psychiatry 12: 81–91.CrossRefGoogle Scholar
  68. Rondot P (1988) Electrological approach to tardive dyskinesia (TD). Encéphale 14: 183–189.PubMedGoogle Scholar
  69. Rudick RA, Breton D, Krall RL (1987) The GABA agonist progabide for spasticity in multiple sclerosis. Arch Neurol 44: 1033–1036.PubMedCrossRefGoogle Scholar
  70. Sanger DJ, Joly D, Zivkovic B (1986) Effects of zolpidem, a new imidazopyridine hypnotic, on the acquisition of conditioned fear in mice. Comparison with triazolam and CL 218,872. Psychopharmacology 90: 207–210.Google Scholar
  71. Santori EM, Collins RC (1988) Effects of chronic cortical seizures on GABA and benzodiazepine receptors within seizure pathways. Brain Res 442: 261–269.PubMedCrossRefGoogle Scholar
  72. Savic I, Roland P, Sedvall G, Persson A, Pauli S, Widén L (1988) In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 2: 863–866.PubMedCrossRefGoogle Scholar
  73. Scatton B, Claustre Y, Graham D, Dennis T, Serrano A, Arbilla S, Pimoule C, Schoemaker H, Bigg D, Langer SZ (1988) SL 81.0385: a novel selective and potent serotonin uptake inhibitor. Drug Dev Res 12: 29–40.CrossRefGoogle Scholar
  74. Silva-Barrat C, Brailowsky S, Riche D, Menini Ch (1988) Anticonvulsant effects of localized chronic infusions of GABA in cortical and reticular structures of baboons. Exp Neurol 101: 418–427.PubMedCrossRefGoogle Scholar
  75. Tassinari CA, Michelucci R, Ambrosetto G, Salvi F (1987) Double-blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol 44: 907–910.PubMedCrossRefGoogle Scholar
  76. Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA (1987) Brain γ-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry 44: 522–529.PubMedCrossRefGoogle Scholar
  77. Thiébot MH (1985) Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev 9: 95–100.PubMedCrossRefGoogle Scholar
  78. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiat Scand 78: 121–137.PubMedCrossRefGoogle Scholar
  79. Ueda H, Ge M, Satoh M, Takagi H (1987) Subconvulsive doses of intracisternal bicuculline methiodide, a GABAA receptor antagonist, produce potent analgesia as measured in the tail pinch test in mice. Eur J Pharmacol 136: 129–131.PubMedCrossRefGoogle Scholar
  80. Vernier P, Julien J-F, Rataboul P, Fourrier O, Feuerstein C, Mallet J (1988) Similar time course changes in striatal levels of glutamic acid decarboxylase and proenkephalin mRNA following dopaminergic deafferentation in the rat. J Neurochem 51: 1375–1380.PubMedCrossRefGoogle Scholar
  81. Waszczak BL, Walters JR (1986) Endogenous dopamine can modulate inhibition of sub-stantia nigra pars reticulata neurons elicited by GABA iontophoresis or striatal stimulation. J Neurosci 6: 120–126.PubMedGoogle Scholar
  82. Yamamoto T, Amakusa T, Iizuka R, Nagatsu T (1985) Free and total GABA in cerebro-spinal fluid of patients with dementia. Biogenic Amines 2: 125–129.Google Scholar
  83. Zarrindast MR, Djavdan M (1988) GABAA antagonists and baclofen analgesia. Gen Pharmacol 19: 703–706.PubMedCrossRefGoogle Scholar
  84. Ziegler M, Fournier V, Bathien N, Morselli PL, Rondot P (1987) Therapeutic response to progabide in neuroleptic-and L-DOPA-induced dyskinesias. Clin Neuropharmacol 10: 238–246.PubMedCrossRefGoogle Scholar
  85. Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T, Lauter H (1984) γ-Ami-nobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer’s type. Arch Neurol 41: 602–604.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • K. G. Lloyd
    • 1
    • 2
  • P. Pichat
    • 1
  • B. Scatton
    • 1
  • B. Zivkovic
    • 1
  • P. L. Morselli
    • 1
  • G. Bartholini
    • 1
  1. 1.Synthélabo Recherche (L.E.R.S.)ParisFrance
  2. 2.Synthélabo Recherche (L.E.R.S.)ParisFrance

Personalised recommendations